{"license":"https://creativecommons.org/licenses/by/4.0/","dataset":"atlas","updatedThrough":"2026-08-15","guardrail":"The atlas exposes only relationships declared in the current public data. A link or issue grouping does not make unlike measures comparable, establish ownership or control, define an antitrust market, assign liability, or show that a policy event caused an economic outcome.","filters":{"depth":2,"edgeType":"all","edgeTypeMatched":true,"focus":"policy_record:evt-pbm-caremark-settlement-2026","focusMatched":true,"kind":"all","kindMatched":true,"layer":"all","layerMatched":true,"query":"","view":"network"},"summary":{"nodeCount":5478,"edgeCount":19193,"sourceCount":45,"profileCount":5433,"nodeKindCount":13,"layerCount":4,"eligibleEdgeCount":19193,"matchedNodeCount":14,"plottedEdgeCount":19,"plottedNodeCount":14,"hiddenNodeCount":0,"directNeighborCount":4},"focusNode":{"id":"policy_record:evt-pbm-caremark-settlement-2026","kind":"policy_record","label":"FTC announces proposed consent agreement with Caremark","shortLabel":"FTC announces proposed c...","description":"The FTC announced a proposed consent agreement with Caremark and Zinc Health Services addressing formulary design, point-of-sale rebates, fee structures, plan-sponsor transparency, community-pharmacy reimbursement, and access to pharmacy hub services.","href":"/enforcement/records/pbm-caremark-settlement-2026","metricLabel":"Official stage","metricValue":"remedy","detail":"Federal Trade Commission / 2026-07-14","status":"settlement","year":2026,"color":"#f43f5e","searchText":"evt-pbm-caremark-settlement-2026 ftc announces proposed consent agreement with caremark federal trade commission settlement remedy the ftc announced a proposed consent agreement with caremark and zinc health services addressing formulary design, point-of-sale rebates, fee structures, plan-sponsor transparency, community-pharmacy reimbursement, and access to pharmacy hub services. docket no. 9437","connectionCount":4},"nodes":[{"id":"policy_record:evt-pbm-caremark-settlement-2026","kind":"policy_record","label":"FTC announces proposed consent agreement with Caremark","shortLabel":"FTC announces proposed c...","description":"The FTC announced a proposed consent agreement with Caremark and Zinc Health Services addressing formulary design, point-of-sale rebates, fee structures, plan-sponsor transparency, community-pharmacy reimbursement, and access to pharmacy hub services.","href":"/enforcement/records/pbm-caremark-settlement-2026","metricLabel":"Official stage","metricValue":"remedy","detail":"Federal Trade Commission / 2026-07-14","status":"settlement","year":2026,"color":"#f43f5e","searchText":"evt-pbm-caremark-settlement-2026 ftc announces proposed consent agreement with caremark federal trade commission settlement remedy the ftc announced a proposed consent agreement with caremark and zinc health services addressing formulary design, point-of-sale rebates, fee structures, plan-sponsor transparency, community-pharmacy reimbursement, and access to pharmacy hub services. docket no. 9437","connectionCount":4,"distance":0,"labelVisible":true,"radius":20,"x":450,"y":260},{"id":"market:mkt-pbm","kind":"market","label":"U.S. pharmacy benefit management","shortLabel":"PBMs","description":"Pharmacy benefit management services profile based on FTC public findings. The FTC reports top-three and top-six aggregate shares but not enough individual PBM market shares in the public press-release record to compute HHI.","href":"/markets/us-pharmacy-benefit-management","metricLabel":"HHI status","metricValue":"Withheld","detail":"United States / 2023","status":"incomplete","year":2023,"color":"#14b8a6","searchText":"u.s. pharmacy benefit management pbms health care united states pharmacy benefit management services profile based on ftc public findings. the ftc reports top-three and top-six aggregate shares but not enough individual pbm market shares in the public press-release record to compute hhi.","connectionCount":10,"x":450,"y":112,"distance":1,"radius":11,"labelVisible":true},{"id":"policy_entity:pent-caremark-rx","kind":"policy_entity","label":"Caremark Rx, LLC","shortLabel":"Caremark Rx, LLC","description":"Pharmacy benefit manager named in FTC study and administrative complaint records.","href":"/enforcement/entities/caremark-rx-llc","metricLabel":"Named records","metricValue":"3","detail":"Official-record organization label","status":"record-only label","year":null,"color":"#ec4899","searchText":"caremark rx, llc pharmacy benefit manager named in ftc study and administrative complaint records. report_subject respondent remedy_subject","connectionCount":3,"x":598,"y":260,"distance":1,"radius":11,"labelVisible":true},{"id":"policy_entity:pent-zinc-health","kind":"policy_entity","label":"Zinc Health Services, LLC","shortLabel":"Zinc Health Services...","description":"Group purchasing organization named in the FTC insulin administrative complaint record.","href":"/enforcement/entities/zinc-health-services-llc","metricLabel":"Named records","metricValue":"2","detail":"Official-record organization label","status":"record-only label","year":null,"color":"#ec4899","searchText":"zinc health services, llc group purchasing organization named in the ftc insulin administrative complaint record. respondent remedy_subject","connectionCount":2,"x":450,"y":408,"distance":1,"radius":11,"labelVisible":true},{"id":"source:ftc-caremark-settlement-2026","kind":"source","label":"FTC Secures Major Settlement with Caremark Resolving Antitrust Case Against Second Drug Middleman","shortLabel":"Federal Trade Commission","description":"FTC announcement and proposed consent-order record resolving the administrative action against Caremark and Zinc Health Services.","href":"/sources/ftc-caremark-settlement-2026","metricLabel":"Access date","metricValue":"2026-07-20","detail":"Federal Trade Commission","status":"agency report","year":2026,"color":"#64748b","searchText":"ftc-caremark-settlement-2026 ftc secures major settlement with caremark resolving antitrust case against second drug middleman federal trade commission ftc announcement and proposed consent-order record resolving the administrative action against caremark and zinc health services. federal trade commission, ftc secures major settlement with caremark resolving antitrust case against second drug middleman, july 14 2026. agency_report","connectionCount":1,"x":302,"y":260,"distance":1,"radius":11,"labelVisible":true},{"id":"industry:524292","kind":"industry","label":"Pharmacy benefit management and other third party administration of insurance and pension funds","shortLabel":"524292 Pharmacy benefi...","description":"2022 Economic Census employer-firm concentration screen for NAICS 524292.","href":"/industries/524292","metricLabel":"Revenue HHI","metricValue":"1,633.5","detail":"2.5K firms / 283.6B revenue","status":"published","year":2022,"color":"#f59e0b","searchText":"524292 pharmacy benefit management and other third party administration of insurance and pension funds 52","connectionCount":5,"x":471.391,"y":22.963,"distance":2,"radius":8,"labelVisible":false},{"id":"issue:health-care-intermediaries","kind":"issue","label":"Health care intermediaries","shortLabel":"Health intermediaries","description":"How do insurer structure, PBM contracting, rebate, formulary, network, and organizational relationships affect competition and patient access across separately measured health-care systems?","href":"/issues/health-care-intermediaries","metricLabel":"Bounded markets","metricValue":"2","detail":"2 separately defined markets / editorial research program","status":"issue program","year":2024,"color":"#c026d3","searchText":"health care intermediaries health intermediaries insurance, pbm contracting, access, and public-data gaps the program connects the 2024 kff state individual-insurance concentration cross-section to separately bounded public pbm facts, named official records, source limits, and evidence requests without treating payer and prescription-intermediary systems as one market. how do insurer structure, pbm contracting, rebate, formulary, network, and organizational relationships affect competition and patient access across separately measured health-care systems? which comparable state insurer enrollment, claims, prescription, rebate, and network records can establish firm-level structure under stable ownership identifiers? how do plan entry, insurer structure, contracting, formulary, and network practices differ across payer, pharmacy, patient, and geographic segments? which ownership and control relationships are supported by exact filings rather than name similarity or market context? u.s. pharmacy benefit management pbms health care u.s. aca individual health insurance individual insurance health insurance","connectionCount":4,"x":618.751,"y":92.169,"distance":2,"radius":8,"labelVisible":false},{"id":"policy_record:evt-pbm-insulin-complaint-2024","kind":"policy_record","label":"FTC files administrative complaint against the three largest PBMs","shortLabel":"FTC files administrative...","description":"The FTC brought an administrative action alleging anticompetitive and unfair rebating and formulary practices involving Caremark, Express Scripts, OptumRx, and affiliated GPOs.","href":"/enforcement/records/pbm-insulin-complaint-2024","metricLabel":"Official stage","metricValue":"litigation","detail":"Federal Trade Commission / 2024-09-20","status":"complaint","year":2024,"color":"#f43f5e","searchText":"evt-pbm-insulin-complaint-2024 ftc files administrative complaint against the three largest pbms federal trade commission complaint litigation the ftc brought an administrative action alleging anticompetitive and unfair rebating and formulary practices involving caremark, express scripts, optumrx, and affiliated gpos. docket no. 9437","connectionCount":8,"x":687.15,"y":239.905,"distance":2,"radius":8,"labelVisible":false},{"id":"policy_record:evt-pbm-interim-report-2024","kind":"policy_record","label":"FTC releases interim staff report on prescription drug middlemen","shortLabel":"FTC releases interim sta...","description":"The FTC published interim findings on PBM concentration and vertical integration, including aggregate shares for the largest PBMs.","href":"/enforcement/records/pbm-interim-report-2024","metricLabel":"Official stage","metricValue":"monitoring","detail":"Federal Trade Commission / 2024-07-09","status":"report","year":2024,"color":"#f43f5e","searchText":"evt-pbm-interim-report-2024 ftc releases interim staff report on prescription drug middlemen federal trade commission report monitoring the ftc published interim findings on pbm concentration and vertical integration, including aggregate shares for the largest pbms.","connectionCount":8,"x":644.584,"y":397.044,"distance":2,"radius":8,"labelVisible":false},{"id":"policy_record:evt-pbm-express-scripts-settlement-2026","kind":"policy_record","label":"FTC announces proposed consent agreement with Express Scripts","shortLabel":"FTC announces proposed c...","description":"The FTC announced a proposed consent agreement with Express Scripts and affiliated entities addressing formulary design, patient cost sharing, manufacturer compensation, plan-sponsor transparency, community-pharmacy reimbursement, and related business practices.","href":"/enforcement/records/pbm-express-scripts-settlement-2026","metricLabel":"Official stage","metricValue":"remedy","detail":"Federal Trade Commission / 2026-02-04","status":"settlement","year":2026,"color":"#f43f5e","searchText":"evt-pbm-express-scripts-settlement-2026 ftc announces proposed consent agreement with express scripts federal trade commission settlement remedy the ftc announced a proposed consent agreement with express scripts and affiliated entities addressing formulary design, patient cost sharing, manufacturer compensation, plan-sponsor transparency, community-pharmacy reimbursement, and related business practices. docket no. 9437","connectionCount":4,"x":510.97,"y":490.058,"distance":2,"radius":8,"labelVisible":false},{"id":"report:rep-us-competition-landscape-2026","kind":"report","label":"The U.S. Competition Landscape","shortLabel":"The U.S. Competition La...","description":"A national briefing that aligns defined-market signals, industry structure, state and local geographic concentration screens, merger activity, and enforcement records without collapsing their different scopes.","href":"/reports/us-competition-landscape-2026","metricLabel":"Evidence sources","metricValue":"14","detail":"8 linked markets","status":"published","year":2026,"color":"#6366f1","searchText":"the u.s. competition landscape state of competition 2026: five evidence systems, no single score a national briefing that aligns defined-market signals, industry structure, state and local geographic concentration screens, merger activity, and enforcement records without collapsing their different scopes. a source-backed state-of-competition briefing across markets, industries, state systems, local banking screens, mergers, and enforcement, with every system kept in its own analytical universe. 2022 and 2017 u.s. economic census industry concentration tables, usda ers historical meatpacking cr4, kff 2024 state individual-market hhi, fdic 2025 statewide and county summary of deposits screens, the fy2025 ftc/doj hsr report, and source-backed market and enforcement records.","connectionCount":26,"x":348.828,"y":475.425,"distance":2,"radius":8,"labelVisible":false},{"id":"report:rep-public-data-gaps","kind":"report","label":"Where Public Market-Share Data Runs Out","shortLabel":"Where Public Market-Sha...","description":"An open report explaining why the observatory sometimes withholds HHI even when public facts indicate concentration.","href":"/reports/public-data-gaps","metricLabel":"Evidence sources","metricValue":"2","detail":"2 linked markets","status":"published","year":2026,"color":"#6366f1","searchText":"where public market-share data runs out why incomplete profiles are part of the product an open report explaining why the observatory sometimes withholds hhi even when public facts indicate concentration. a transparency note on incomplete data and why the observatory never fills gaps with invented shares. bts public airline market-share table and ftc pbm interim staff report materials.","connectionCount":5,"x":234.025,"y":359.993,"distance":2,"radius":8,"labelVisible":false},{"id":"source:bls-cpi-public-data-2026","kind":"source","label":"Consumer Price Index, U.S. city average monthly series","shortLabel":"U.S. Bureau of Labor...","description":"Official non-seasonally-adjusted monthly Consumer Price Index series for nine U.S. city average item universes from January 2017 through July 2026, including publisher-declared and unreturned monthly gaps.","href":"/sources/bls-cpi-public-data-2026","metricLabel":"Access date","metricValue":"2026-08-13","detail":"U.S. Bureau of Labor Statistics","status":"public dataset","year":2026,"color":"#64748b","searchText":"bls-cpi-public-data-2026 consumer price index, u.s. city average monthly series u.s. bureau of labor statistics official non-seasonally-adjusted monthly consumer price index series for nine u.s. city average item universes from january 2017 through july 2026, including publisher-declared and unreturned monthly gaps. u.s. bureau of labor statistics, consumer price index public data, u.s. city average monthly series, accessed august 13 2026. public_dataset","connectionCount":10,"x":220.279,"y":197.773,"distance":2,"radius":8,"labelVisible":false},{"id":"source:ftc-pbm-interim-2024","kind":"source","label":"Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies","shortLabel":"Federal Trade Commission","description":"FTC interim staff report and press release on PBM concentration and vertical integration.","href":"/sources/ftc-pbm-interim-2024","metricLabel":"Access date","metricValue":"2026-05-16","detail":"Federal Trade Commission","status":"agency report","year":2026,"color":"#64748b","searchText":"ftc-pbm-interim-2024 pharmacy benefit managers: the powerful middlemen inflating drug costs and squeezing main street pharmacies federal trade commission ftc interim staff report and press release on pbm concentration and vertical integration. federal trade commission, ftc releases interim staff report on prescription drug middlemen, july 9 2024. agency_report","connectionCount":4,"x":314.022,"y":64.669,"distance":2,"radius":8,"labelVisible":false}],"rows":[{"id":"named-in-record:peel-caremark-complaint","layer":"enforcement","relationshipType":"named_in_record","relationshipLabel":"respondent","fromId":"policy_record:evt-pbm-insulin-complaint-2024","fromKind":"policy_record","fromLabel":"FTC files administrative complaint against the three largest PBMs","fromHref":"/enforcement/records/pbm-insulin-complaint-2024","toId":"policy_entity:pent-caremark-rx","toKind":"policy_entity","toLabel":"Caremark Rx, LLC","toHref":"/enforcement/entities/caremark-rx-llc","evidenceLabel":"Exact official-record relationship","evidenceDetail":"The FTC administrative complaint names Caremark Rx as a respondent.","sourceId":"ftc-pbm-insulin-complaint-2024","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2024/09/ftc-sues-prescription-drug-middlemen-artificially-inflating-insulin-drug-prices","confidenceLevel":"bounded","indicatorId":null,"entityCode":null,"observationCount":null,"firstYear":null,"latestYear":null,"preferredView":null,"sourceIds":null,"guardrail":"A named-organization edge records the role encoded from one official record; it is not an independent liability or identity finding."},{"id":"named-in-record:peel-caremark-report","layer":"enforcement","relationshipType":"named_in_record","relationshipLabel":"report subject","fromId":"policy_record:evt-pbm-interim-report-2024","fromKind":"policy_record","fromLabel":"FTC releases interim staff report on prescription drug middlemen","fromHref":"/enforcement/records/pbm-interim-report-2024","toId":"policy_entity:pent-caremark-rx","toKind":"policy_entity","toLabel":"Caremark Rx, LLC","toHref":"/enforcement/entities/caremark-rx-llc","evidenceLabel":"Exact official-record relationship","evidenceDetail":"The FTC interim report identifies Caremark Rx among the six PBMs that received Section 6(b) orders.","sourceId":"ftc-pbm-interim-2024","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2024/07/ftc-releases-interim-staff-report-prescription-drug-middlemen","confidenceLevel":"bounded","indicatorId":null,"entityCode":null,"observationCount":null,"firstYear":null,"latestYear":null,"preferredView":null,"sourceIds":null,"guardrail":"A named-organization edge records the role encoded from one official record; it is not an independent liability or identity finding."},{"id":"named-in-record:peel-caremark-settlement","layer":"enforcement","relationshipType":"named_in_record","relationshipLabel":"remedy subject","fromId":"policy_record:evt-pbm-caremark-settlement-2026","fromKind":"policy_record","fromLabel":"FTC announces proposed consent agreement with Caremark","fromHref":"/enforcement/records/pbm-caremark-settlement-2026","toId":"policy_entity:pent-caremark-rx","toKind":"policy_entity","toLabel":"Caremark Rx, LLC","toHref":"/enforcement/entities/caremark-rx-llc","evidenceLabel":"Exact official-record relationship","evidenceDetail":"The FTC settlement announcement identifies Caremark among the entities subject to the proposed consent agreement.","sourceId":"ftc-caremark-settlement-2026","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2026/07/ftc-secures-major-settlement-caremark-resolving-antitrust-case-against-second-drug-middleman","confidenceLevel":"bounded","indicatorId":null,"entityCode":null,"observationCount":null,"firstYear":null,"latestYear":null,"preferredView":null,"sourceIds":null,"guardrail":"A named-organization edge records the role encoded from one official record; it is not an independent liability or identity finding."},{"id":"named-in-record:peel-zinc-complaint","layer":"enforcement","relationshipType":"named_in_record","relationshipLabel":"respondent","fromId":"policy_record:evt-pbm-insulin-complaint-2024","fromKind":"policy_record","fromLabel":"FTC files administrative complaint against the three largest PBMs","fromHref":"/enforcement/records/pbm-insulin-complaint-2024","toId":"policy_entity:pent-zinc-health","toKind":"policy_entity","toLabel":"Zinc Health Services, LLC","toHref":"/enforcement/entities/zinc-health-services-llc","evidenceLabel":"Exact official-record relationship","evidenceDetail":"The FTC administrative complaint names affiliated GPO Zinc Health Services as a respondent.","sourceId":"ftc-pbm-insulin-complaint-2024","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2024/09/ftc-sues-prescription-drug-middlemen-artificially-inflating-insulin-drug-prices","confidenceLevel":"bounded","indicatorId":null,"entityCode":null,"observationCount":null,"firstYear":null,"latestYear":null,"preferredView":null,"sourceIds":null,"guardrail":"A named-organization edge records the role encoded from one official record; it is not an independent liability or identity finding."},{"id":"named-in-record:peel-zinc-settlement","layer":"enforcement","relationshipType":"named_in_record","relationshipLabel":"remedy subject","fromId":"policy_record:evt-pbm-caremark-settlement-2026","fromKind":"policy_record","fromLabel":"FTC announces proposed consent agreement with Caremark","fromHref":"/enforcement/records/pbm-caremark-settlement-2026","toId":"policy_entity:pent-zinc-health","toKind":"policy_entity","toLabel":"Zinc Health Services, LLC","toHref":"/enforcement/entities/zinc-health-services-llc","evidenceLabel":"Exact official-record relationship","evidenceDetail":"The FTC settlement announcement identifies affiliated group purchasing organization Zinc Health Services among the entities subject to the proposed consent agreement.","sourceId":"ftc-caremark-settlement-2026","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2026/07/ftc-secures-major-settlement-caremark-resolving-antitrust-case-against-second-drug-middleman","confidenceLevel":"bounded","indicatorId":null,"entityCode":null,"observationCount":null,"firstYear":null,"latestYear":null,"preferredView":null,"sourceIds":null,"guardrail":"A named-organization edge records the role encoded from one official record; it is not an independent liability or identity finding."},{"id":"policy-scope:evt-pbm-caremark-settlement-2026:mkt-pbm","layer":"enforcement","relationshipType":"policy_scope","relationshipLabel":"Related policy context","fromId":"market:mkt-pbm","fromKind":"market","fromLabel":"U.S. pharmacy benefit management","fromHref":"/markets/us-pharmacy-benefit-management","toId":"policy_record:evt-pbm-caremark-settlement-2026","toKind":"policy_record","toLabel":"FTC announces proposed consent agreement with Caremark","toHref":"/enforcement/records/pbm-caremark-settlement-2026","evidenceLabel":"Federal Trade Commission / 2026-07-14","evidenceDetail":"Records announced remedy terms in the pending administrative matter. The filing does not establish realized savings, changes in PBM market structure, or a basis for calculating the withheld market HHI.","sourceId":"ftc-caremark-settlement-2026","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2026/07/ftc-secures-major-settlement-caremark-resolving-antitrust-case-against-second-drug-middleman","confidenceLevel":"bounded","indicatorId":null,"entityCode":null,"observationCount":null,"firstYear":null,"latestYear":null,"preferredView":null,"sourceIds":null,"guardrail":"A related-market edge records the observatory's bounded context for a dated official event; it does not show causal effects on concentration."},{"id":"policy-scope:evt-pbm-express-scripts-settlement-2026:mkt-pbm","layer":"enforcement","relationshipType":"policy_scope","relationshipLabel":"Related policy context","fromId":"market:mkt-pbm","fromKind":"market","fromLabel":"U.S. pharmacy benefit management","fromHref":"/markets/us-pharmacy-benefit-management","toId":"policy_record:evt-pbm-express-scripts-settlement-2026","toKind":"policy_record","toLabel":"FTC announces proposed consent agreement with Express Scripts","toHref":"/enforcement/records/pbm-express-scripts-settlement-2026","evidenceLabel":"Federal Trade Commission / 2026-02-04","evidenceDetail":"Records announced remedy terms in the pending administrative matter. The filing does not establish realized savings, changes in PBM market structure, or a basis for calculating the withheld market HHI.","sourceId":"ftc-express-scripts-settlement-2026","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2026/02/ftc-secures-landmark-settlement-express-scripts-lower-drug-costs-american-patients","confidenceLevel":"bounded","indicatorId":null,"entityCode":null,"observationCount":null,"firstYear":null,"latestYear":null,"preferredView":null,"sourceIds":null,"guardrail":"A related-market edge records the observatory's bounded context for a dated official event; it does not show causal effects on concentration."},{"id":"policy-scope:evt-pbm-insulin-complaint-2024:mkt-pbm","layer":"enforcement","relationshipType":"policy_scope","relationshipLabel":"Related policy context","fromId":"market:mkt-pbm","fromKind":"market","fromLabel":"U.S. pharmacy benefit management","fromHref":"/markets/us-pharmacy-benefit-management","toId":"policy_record:evt-pbm-insulin-complaint-2024","toKind":"policy_record","toLabel":"FTC files administrative complaint against the three largest PBMs","toHref":"/enforcement/records/pbm-insulin-complaint-2024","evidenceLabel":"Federal Trade Commission / 2024-09-20","evidenceDetail":"Adds alleged conduct and patient-harm context to the PBM profile. The allegations remain distinct from the descriptive concentration evidence and do not supply missing individual shares.","sourceId":"ftc-pbm-insulin-complaint-2024","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2024/09/ftc-sues-prescription-drug-middlemen-artificially-inflating-insulin-drug-prices","confidenceLevel":"bounded","indicatorId":null,"entityCode":null,"observationCount":null,"firstYear":null,"latestYear":null,"preferredView":null,"sourceIds":null,"guardrail":"A related-market edge records the observatory's bounded context for a dated official event; it does not show causal effects on concentration."},{"id":"policy-scope:evt-pbm-interim-report-2024:mkt-pbm","layer":"enforcement","relationshipType":"policy_scope","relationshipLabel":"Related policy context","fromId":"market:mkt-pbm","fromKind":"market","fromLabel":"U.S. pharmacy benefit management","fromHref":"/markets/us-pharmacy-benefit-management","toId":"policy_record:evt-pbm-interim-report-2024","toKind":"policy_record","toLabel":"FTC releases interim staff report on prescription drug middlemen","toHref":"/enforcement/records/pbm-interim-report-2024","evidenceLabel":"Federal Trade Commission / 2024-07-09","evidenceDetail":"Supplies top-three and top-six concentration facts while leaving individual firm shares unavailable; Antitrust Radar therefore continues to withhold HHI.","sourceId":"ftc-pbm-interim-2024","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2024/07/ftc-releases-interim-staff-report-prescription-drug-middlemen","confidenceLevel":"bounded","indicatorId":null,"entityCode":null,"observationCount":null,"firstYear":null,"latestYear":null,"preferredView":null,"sourceIds":null,"guardrail":"A related-market edge records the observatory's bounded context for a dated official event; it does not show causal effects on concentration."},{"id":"record-source:evt-pbm-caremark-settlement-2026:ftc-caremark-settlement-2026","layer":"enforcement","relationshipType":"record_source","relationshipLabel":"Official record source","fromId":"policy_record:evt-pbm-caremark-settlement-2026","fromKind":"policy_record","fromLabel":"FTC announces proposed consent agreement with Caremark","fromHref":"/enforcement/records/pbm-caremark-settlement-2026","toId":"source:ftc-caremark-settlement-2026","toKind":"source","toLabel":"FTC Secures Major Settlement with Caremark Resolving Antitrust Case Against Second Drug Middleman","toHref":"/sources/ftc-caremark-settlement-2026","evidenceLabel":"Federal Trade Commission","evidenceDetail":"FTC Secures Major Settlement with Caremark Resolving Antitrust Case Against Second Drug Middleman is the custody record encoded for this dated policy event.","sourceId":"ftc-caremark-settlement-2026","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2026/07/ftc-secures-major-settlement-caremark-resolving-antitrust-case-against-second-drug-middleman","confidenceLevel":"high","indicatorId":null,"entityCode":null,"observationCount":null,"firstYear":null,"latestYear":null,"preferredView":null,"sourceIds":null,"guardrail":"The source is the official custody record for the encoded event; later outcomes require separate evidence."},{"id":"record-source:evt-pbm-interim-report-2024:ftc-pbm-interim-2024","layer":"enforcement","relationshipType":"record_source","relationshipLabel":"Official record source","fromId":"policy_record:evt-pbm-interim-report-2024","fromKind":"policy_record","fromLabel":"FTC releases interim staff report on prescription drug middlemen","fromHref":"/enforcement/records/pbm-interim-report-2024","toId":"source:ftc-pbm-interim-2024","toKind":"source","toLabel":"Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies","toHref":"/sources/ftc-pbm-interim-2024","evidenceLabel":"Federal Trade Commission","evidenceDetail":"Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies is the custody record encoded for this dated policy event.","sourceId":"ftc-pbm-interim-2024","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2024/07/ftc-releases-interim-staff-report-prescription-drug-middlemen","confidenceLevel":"high","indicatorId":null,"entityCode":null,"observationCount":null,"firstYear":null,"latestYear":null,"preferredView":null,"sourceIds":null,"guardrail":"The source is the official custody record for the encoded event; later outcomes require separate evidence."},{"id":"consumer-price-context:mkt-pbm:prescription-drugs","layer":"measurement","relationshipType":"consumer_price_context","relationshipLabel":"Consumer price context","fromId":"market:mkt-pbm","fromKind":"market","fromLabel":"U.S. pharmacy benefit management","fromHref":"/markets/us-pharmacy-benefit-management","toId":"source:bls-cpi-public-data-2026","toKind":"source","toLabel":"Consumer Price Index, U.S. city average monthly series","toHref":"/sources/bls-cpi-public-data-2026","evidenceLabel":"U.S. Bureau of Labor Statistics / CUUR0000SEMF01","evidenceDetail":"Prescription drugs is attached to PBMs as a broad BLS consumer-price context series. Retail prescription-drug prices are attached as consumer context for the PBM dossier; they do not measure PBM services, rebates, spreads, pharmacy reimbursement, margins, or competitive effects.","sourceId":"bls-cpi-public-data-2026","sourceUrl":"https://www.bls.gov/cpi/data.htm","confidenceLevel":"bounded","indicatorId":null,"entityCode":null,"observationCount":null,"firstYear":null,"latestYear":null,"preferredView":null,"sourceIds":null,"guardrail":"A broad consumer-price series is attached only as descriptive context. It does not establish product equivalence, an antitrust market, concentration, market power, margins, pass-through, welfare, competitive effects, or causation."},{"id":"industry-screen:mkt-pbm:524292","layer":"measurement","relationshipType":"industry_screen","relationshipLabel":"Declared Census screen","fromId":"market:mkt-pbm","fromKind":"market","fromLabel":"U.S. pharmacy benefit management","fromHref":"/markets/us-pharmacy-benefit-management","toId":"industry:524292","toKind":"industry","toLabel":"Pharmacy benefit management and other third party administration of insurance and pension funds","toHref":"/industries/524292","evidenceLabel":"Market definition crosswalk","evidenceDetail":"U.S. pharmacy benefit management uses NAICS 524292 as declared economy-wide context while preserving a separate product and geographic definition.","sourceId":"ftc-pbm-interim-2024","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2024/07/ftc-releases-interim-staff-report-prescription-drug-middlemen","confidenceLevel":"high","indicatorId":null,"entityCode":null,"observationCount":null,"firstYear":null,"latestYear":null,"preferredView":null,"sourceIds":null,"guardrail":"A declared NAICS link supplies economy-wide screening context and is not a legal product or geographic market definition."},{"id":"market-source:mkt-pbm:ftc-pbm-interim-2024","layer":"measurement","relationshipType":"market_source","relationshipLabel":"Market evidence custody","fromId":"market:mkt-pbm","fromKind":"market","fromLabel":"U.S. pharmacy benefit management","fromHref":"/markets/us-pharmacy-benefit-management","toId":"source:ftc-pbm-interim-2024","toKind":"source","toLabel":"Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies","toHref":"/sources/ftc-pbm-interim-2024","evidenceLabel":"Federal Trade Commission","evidenceDetail":"Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies supports the profile's definition, observation.","sourceId":"ftc-pbm-interim-2024","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2024/07/ftc-releases-interim-staff-report-prescription-drug-middlemen","confidenceLevel":"bounded","indicatorId":null,"entityCode":null,"observationCount":null,"firstYear":null,"latestYear":null,"preferredView":null,"sourceIds":null,"guardrail":"A source link identifies evidence used by a market profile and does not endorse every claim in the underlying record."},{"id":"issue-scope:health-care-intermediaries:mkt-pbm","layer":"research","relationshipType":"issue_scope","relationshipLabel":"Issue program membership","fromId":"issue:health-care-intermediaries","fromKind":"issue","fromLabel":"Health care intermediaries","fromHref":"/issues/health-care-intermediaries","toId":"market:mkt-pbm","toKind":"market","toLabel":"U.S. pharmacy benefit management","toHref":"/markets/us-pharmacy-benefit-management","evidenceLabel":"Competition issue scope contract","evidenceDetail":"U.S. pharmacy benefit management is an explicitly curated member of the Health care intermediaries research program while retaining its own product boundary, geography, denominator, and comparison contract.","sourceId":null,"sourceUrl":null,"confidenceLevel":"bounded","indicatorId":null,"entityCode":null,"observationCount":null,"firstYear":null,"latestYear":null,"preferredView":null,"sourceIds":null,"guardrail":"An editorial issue membership supports research navigation only; it does not combine the member markets, define a broader antitrust market, or establish competitive harm or causation."},{"id":"report-market:rep-public-data-gaps:mkt-pbm","layer":"research","relationshipType":"report_market","relationshipLabel":"Covered market profile","fromId":"report:rep-public-data-gaps","fromKind":"report","fromLabel":"Where Public Market-Share Data Runs Out","fromHref":"/reports/public-data-gaps","toId":"market:mkt-pbm","toKind":"market","toLabel":"U.S. pharmacy benefit management","toHref":"/markets/us-pharmacy-benefit-management","evidenceLabel":"Report scope contract","evidenceDetail":"Where Public Market-Share Data Runs Out explicitly lists U.S. pharmacy benefit management in its related-market scope.","sourceId":null,"sourceUrl":null,"confidenceLevel":"bounded","indicatorId":null,"entityCode":null,"observationCount":null,"firstYear":null,"latestYear":null,"preferredView":null,"sourceIds":null,"guardrail":"A publication link identifies an explicitly covered market profile and does not make separately defined markets interchangeable."},{"id":"report-market:rep-us-competition-landscape-2026:mkt-pbm","layer":"research","relationshipType":"report_market","relationshipLabel":"Covered market profile","fromId":"report:rep-us-competition-landscape-2026","fromKind":"report","fromLabel":"The U.S. Competition Landscape","fromHref":"/reports/us-competition-landscape-2026","toId":"market:mkt-pbm","toKind":"market","toLabel":"U.S. pharmacy benefit management","toHref":"/markets/us-pharmacy-benefit-management","evidenceLabel":"Report scope contract","evidenceDetail":"The U.S. Competition Landscape explicitly lists U.S. pharmacy benefit management in its related-market scope.","sourceId":null,"sourceUrl":null,"confidenceLevel":"bounded","indicatorId":null,"entityCode":null,"observationCount":null,"firstYear":null,"latestYear":null,"preferredView":null,"sourceIds":null,"guardrail":"A publication link identifies an explicitly covered market profile and does not make separately defined markets interchangeable."},{"id":"report-source:rep-public-data-gaps:ftc-pbm-interim-2024","layer":"research","relationshipType":"report_source","relationshipLabel":"Declared publication source","fromId":"report:rep-public-data-gaps","fromKind":"report","fromLabel":"Where Public Market-Share Data Runs Out","fromHref":"/reports/public-data-gaps","toId":"source:ftc-pbm-interim-2024","toKind":"source","toLabel":"Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies","toHref":"/sources/ftc-pbm-interim-2024","evidenceLabel":"Federal Trade Commission","evidenceDetail":"Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies appears in the report's encoded source basis.","sourceId":"ftc-pbm-interim-2024","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2024/07/ftc-releases-interim-staff-report-prescription-drug-middlemen","confidenceLevel":"bounded","indicatorId":null,"entityCode":null,"observationCount":null,"firstYear":null,"latestYear":null,"preferredView":null,"sourceIds":null,"guardrail":"A source edge records the public evidence basis declared by the publication and does not erase the source's limitations."},{"id":"report-source:rep-us-competition-landscape-2026:ftc-pbm-interim-2024","layer":"research","relationshipType":"report_source","relationshipLabel":"Declared publication source","fromId":"report:rep-us-competition-landscape-2026","fromKind":"report","fromLabel":"The U.S. Competition Landscape","fromHref":"/reports/us-competition-landscape-2026","toId":"source:ftc-pbm-interim-2024","toKind":"source","toLabel":"Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies","toHref":"/sources/ftc-pbm-interim-2024","evidenceLabel":"Federal Trade Commission","evidenceDetail":"Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies appears in the report's encoded source basis.","sourceId":"ftc-pbm-interim-2024","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2024/07/ftc-releases-interim-staff-report-prescription-drug-middlemen","confidenceLevel":"bounded","indicatorId":null,"entityCode":null,"observationCount":null,"firstYear":null,"latestYear":null,"preferredView":null,"sourceIds":null,"guardrail":"A source edge records the public evidence basis declared by the publication and does not erase the source's limitations."}]}